Market Overview

UPDATE: Stifel Reiterates On HealthSouth As Second Quarter Easily Exceeds Projection

Share:
Related HLS
5 NYSE Healthcare Stocks With The Highest ROE
Benzinga's M&A Chatter for Thursday June 11, 2015

In a report published Tuesday, Stifel analyst Robert Mains reiterated a Buy rating on HealthSouth (NYSE: HLS), and raised the price target from $38.00 to $41.00.

In the report, Stifel noted, “HealthSouth reported second quarter earnings well ahead of our estimate. The company reported income from continuing operations per share (its EPS proxy) of $0.81, beating our $0.65 estimate. Excluding an accounting gain, income from continuing operations per share were $0.54 compared to our at-consensus $0.48 estimate. We are raising our earnings estimate and target price, as the company also increased its guidance.”

HealthSouth closed on Monday at $37.64.

Latest Ratings for HLS

DateFirmActionFromTo
Jun 2015Deutsche BankMaintainsHold
Jun 2015WedbushInitiates Coverage onNeutral
Jun 2015UBSMaintainsNeutral

View More Analyst Ratings for HLS
View the Latest Analyst Ratings

Posted-In: Robert Mains StifelAnalyst Color Price Target Analyst Ratings

 

Related Articles (HLS)

Around the Web, We're Loving...

Get Benzinga's Newsletters